SCHEDULE: Soleus Capital Files Joint Ownership Statement

Soleus Capital entities and Guy Levy have filed a joint Schedule 13G statement, reporting beneficial ownership of 5.8% of Processa Pharmaceuticals, Inc. common stock.

Summary

• This filing is a Joint Filing Agreement for Schedule 13G, indicating that Soleus Capital Master Fund, L.P., along with related entities and Guy Levy, will file jointly.
• The agreement details the responsibilities for timely filing and accuracy of information concerning each party.
• The filing also incorporates by reference information from the Schedule 13G, which reports beneficial ownership of Processa Pharmaceuticals, Inc. common stock.
• Collectively, the reporting persons beneficially own 160,943 shares, representing 5.8% of the class.
• The reporting persons disclaim beneficial ownership of these shares for purposes other than determining obligations under Section 13(d) of the Exchange Act.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily concerns a joint filing agreement for Schedule 13G, indicating a change in beneficial ownership reporting rather than operational or financial performance updates.

Positives

• Clear disclosure of beneficial ownership, providing transparency to the market.
• The joint filing agreement establishes a framework for coordinated reporting among related entities.

Negatives

• The filing does not provide any operational or financial performance data for Processa Pharmaceuticals, Inc.
• The disclaimer of beneficial ownership for purposes beyond Section 13(d) obligations may create ambiguity for some investors.

Risks

• Potential for future changes in beneficial ownership or investment strategy by Soleus Capital, which could impact Processa Pharmaceuticals, Inc.'s stock.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• Each of SCG, Soleus Capital, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors acquiring a significant stake in a company. This filing indicates Soleus Capital's increased interest in Processa Pharmaceuticals, Inc., but without further context on their investment thesis, the strategic implications remain unclear.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant beneficial owner, potentially influencing market perception and trading activity.
• Management of Processa Pharmaceuticals, Inc.: Awareness of a substantial shareholder group, which may lead to engagement or strategic considerations.

Next Steps

• The reporting persons will continue to file amendments to Schedule 13G as required by regulations.
• Monitoring future filings from Soleus Capital for any changes in beneficial ownership or stated investment intentions.

Key Dates

Keywords

Schedule 13G, Joint Filing Agreement, Beneficial Ownership, Processa Pharmaceuticals, Soleus Capital, Securities Exchange Act